Login / Signup

Drug discovery and development: Biomarkers of neurotoxicity and neurodegeneration.

Abigail L WalkerSyed Z ImamRuth A Roberts
Published in: Experimental biology and medicine (Maywood, N.J.) (2018)
Attrition in drug discovery and development remains a major challenge. Safety/toxicity is the most prevalent reason for failure with cardiovascular and CNS toxicities predominating. Non-invasive biomarkers of neurotoxicity would provide significant advantage by allowing earlier prediction of likely neurotoxicity in preclinical studies as well as facilitating clinical trials of new therapies for neurodegenerative conditions such as Parkinson's disease (PD) and multiple sclerosis (MS).
Keyphrases
  • drug discovery
  • multiple sclerosis
  • clinical trial
  • mass spectrometry
  • ms ms
  • white matter
  • randomized controlled trial
  • stem cells
  • cell therapy
  • bone marrow
  • mesenchymal stem cells
  • phase ii
  • case control
  • phase iii